Sun Pharma to buy & acquire US-based Concert Pharmaceuticals in Rs 4,688 crore / USD 576 million

Sun Pharma to buy & acquire US-based Concert Pharmaceuticals in Rs 4,688 crore / USD 576 million. Tender offers for an upfront payment of USD 8 per share of common stock in cash, or USD 576 million in equity value. Concert stockholders are to receive a non-tradeable contingent value right (CVR) entitling holders to receive up to an additional USD 3.50 per share of common stock in cash, payable upon deuruxolitinib. Concert is a biotechnology company pioneering the use of deuterium in medicinal chemistry. Concert has patent portfolio, including its lead product candidate deuruxolitinib an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease which is in late-stage development. It is dealing in hair loss.

We are financial advisor how can we list our services with you for businessman executing buying, selling shares, mergers and acquisitions?

Yes, you can list your services with us at Email:

plojindexing@gmail.com

How can I register my service as Tax Consultant for traders for wide display?

You can be listed as Tax Consultant with us as per below in this web page and submit your profile at Email:

plojindexing@gmail.com